SCHEMBL21516656

SCHEMBL21516656

Cc1cc(N2CCCOC[C@H]2c2cc(N3CCCC3)ccc2Cl)nc(N)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 2/20 0.44
CRHR2 Q13324 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 3/20 0.40
GFER P55789 1/20 0.40
PRKDC P78527 1/20 0.36
HRH3 Q9Y5N1 4/20 0.36
HRH4 Q9H3N8 3/20 0.34
EHMT2 Q96KQ7 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
SUV39H2 Q9H5I1 1/20 0.33
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
ALOX15 P16050 1/20 0.32
NR4A1 P22736 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21517013 1.00 CRHBP (0.44) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21516394 1.00 CRHBP (0.44) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL29456332 0.95 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21516229 0.95 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL29456671 0.92 CRHBP (0.44) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21516586 0.92 CRHBP (0.44) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21517033 0.89 CRHBP (0.39) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21517101 0.88 CRHBP (0.38) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21516719 0.88 CRHBP (0.38) CRHBPCRHR2SMN1; SMN2MAPTGFER
SCHEMBL21491159 0.88 CRHBP (0.43) CRHBPCRHR2SMN1; SMN2MAPTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 US disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 EP disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-11440907-B1 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 EP disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 EP disclosed
US-10815225-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2020-10-27 US disclosed
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-11440907-B1 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-10815225-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.